Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.

Author:
  • Mats Jerkeman
  • P Aman
  • Eva Cavallin-Ståhl
  • E Torlakovic
  • Måns Åkerman
  • Felix Mitelman
  • Thoas Fioretos
Publishing year: 2002
Language: English
Pages: 161-165
Publication/Series: International Journal of Oncology
Volume: 20
Issue: 1
Document type: Journal article
Publisher: D.A. Spandidos

Abstract english

The purpose of this study was to investigate the prognostic implications of BCL6 rearrangement in a uniformly treated population of patients with diffuse large B-cell lymphoma (DLBCL) and to characterise the relationship between BCL6 rearrangement and prognostic factors. A total of 269 patients with DLBCL entered a randomised trial comparing the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) to the MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) regimen. In 44 cases, frozen tissue was available for assessment of BCL6 status by Southern blot analysis. BCL6 was rearranged in six of 43 evaluable cases (14%), and was associated with elevated lactate dehydrogenase (LDH), and a higher patient age. No association between BCL6 status and expression of BCL2, Ki-67 or TP53 was found. Patients presenting with BCL6 rearrangement displayed a weak trend towards better overall and failure-free survival (67 and 67% at 5 years), compared to patients with germline BCL6 (63 and 52%), but the difference was not statistically significant. In accordance with previously published series, the presence of BCL6 rearrangement does not define a prognostically distinct subgroup of DLBCL. Assessment of BCL6 status may, however, be of clinical interest when related to other prognostic variables.

Keywords

  • Cancer and Oncology
  • Gene Rearrangement B-Lymphocyte : genetics
  • Human
  • Immunophenotyping
  • Lymphoma B-Cell : drug therapy : genetics
  • Leucovorin : therapeutic use
  • Lactate Dehydrogenase : metabolism
  • Lymphoma Large-Cell Diffuse : drug therapy : genetics
  • Male
  • Methotrexate : therapeutic use
  • Middle Age
  • Neoplasm Staging
  • Prednisone : therapeutic use
  • Prognosis
  • Proto-Oncogene Proteins : genetics
  • Support Non-U.S. Gov't
  • Vincristine : therapeutic use
  • Transcription Factors : genetics
  • Doxorubicin : therapeutic use
  • DNA-Binding Proteins : genetics
  • DNA Neoplasm : analysis : metabolism
  • Cyclophosphamide : therapeutic use
  • Blotting Southern
  • Bleomycin : therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols : therapeutic use
  • Aged
  • Adolescence
  • Adult

Other

Published
  • ISSN: 1019-6439
Thoas Fioretos
E-mail: thoas.fioretos [at] med.lu.se

Principal investigator

Division of Clinical Genetics

+46 46 222 45 95

+46 70 334 33 67

BMC C13

66